Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Nov 12, 2026
TickeronGET DAILY SIGNALS
Hyperion DeFi (HYPD) Delivers Record Profits as DeFi Strategy Gains Traction

Hyperion DeFi (HYPD) Delivers Record Profits as DeFi Strategy Gains Traction

Key Takeaways

  • Hyperion DeFi reported third-quarter 2026 revenue of $810,415, up 127% from the prior quarter and 168% year over year.
  • GAAP net income reached a record $39.6 million, driven largely by gains on its HYPE token treasury.
  • Diluted earnings per share came in at $1.23, below the consensus estimate of $1.85, while revenue beat estimates of roughly $661,470.
  • Core operating earnings turned positive for the first time under the company's decentralized finance strategy, at $0.6 million.
  • The company repaid its $8.6 million legacy debt, ended the quarter debt-free, and began buying back shares under a $20 million program.
  • Full-year 2026 adjusted gross profit guidance of $7 million to $8 million was reiterated.

Putting the Quarter in Context

Hyperion DeFi's third-quarter results represent an important checkpoint in the company's shift from a traditional biotech firm to the first U.S.-listed entity building both a strategic treasury and operating businesses on the Hyperliquid blockchain. The numbers stand out because they indicate the core operating model is starting to function independently rather than depending entirely on token price movements. After multiple years of losses and a significant pivot, achieving breakeven on core operations and cash flow one quarter ahead of the year-end target provides concrete validation of the approach. For investors, the report gives a clearer picture of whether the DeFi model can produce sustainable earnings beyond treasury gains. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Breaking Down the Reported Results

Hyperion DeFi reported third-quarter 2026 revenue of $810,415, an increase of 127% from the prior quarter and 168% from $302,506 a year earlier. GAAP net income reached a company record of $39.6 million, up from $31.0 million in the second quarter and $6.6 million in the same period last year. Diluted EPS was $1.23, while basic EPS was $1.24. The company also reported $48.7 million in adjusted EBITDA.

A large portion of the profit came from roughly $44.3 million in realized and unrealized gains on digital assets, reflecting appreciation in its HYPE token holdings. Adjusted gross profit, a non-GAAP measure isolating operating value-add, rose 143% quarter over quarter to $2.8 million, above the $2.0 million to $2.5 million range guided in September. Core operating earnings swung to positive $0.6 million from a loss of $1.2 million in the prior quarter.

The company sold about $13 million of HYPE to retire its roughly $8.6 million Avenue Capital loan, leaving no long-term debt outstanding. It ended the quarter with $14.5 million in cash, cash equivalents, and stablecoins, and held about 1.85 million HYPE tokens valued at $167.9 million. Net asset value stood at $182.4 million. The company also repurchased 240,124 shares in September under its $20 million buyback program.

Market Reaction and Investor Sentiment

Hyperion DeFi shares traded near $2.71 following the report. While the headline profit was a record, the earnings per share figure of $1.23 fell short of the consensus estimate of $1.85, reflecting how much of the gain was tied to mark-to-market movements in the HYPE treasury rather than recurring operating income. Revenue, however, exceeded estimates. Investor sentiment appears focused on the more durable signals in the quarter: the first positive core operating earnings, debt elimination, and the start of share repurchases. The stock's wide 52-week range and elevated beta underscore ongoing volatility tied to digital-asset prices and sentiment around the Hyperliquid ecosystem.

Forward Outlook and Key Factors to Monitor

Hyperion DeFi reiterated its full-year 2026 adjusted gross profit guidance of $7 million to $8 million, roughly six times its 2025 result. With $2.8 million achieved in the third quarter alone, reaching that range depends on sustaining momentum across its five operating segments into the fourth quarter.

Investors should watch several key factors. First, the trajectory of core operating earnings and cash flow will indicate whether the business can generate value independent of HYPE token price swings. Second, the pace of the $20 million buyback program will signal how management views the stock relative to net asset value.

Third, ecosystem developments matter: integrations such as Aave's collaboration with Anchorage Digital, the D3 Frontier Vaults launch partnership, and growing institutional interest in Hyperliquid's HIP-3 and HIP-3 Star markets could expand Hyperion's revenue streams. Finally, digital-asset price volatility remains a central risk, since treasury gains and losses can dramatically swing reported net income from quarter to quarter. From what I see, monitoring these elements closely will help separate operating progress from treasury fluctuations.

Using Tickeron Tools in My Research

One tool I find useful for this kind of analysis is Tickeron’s AI Screener. It helps filter stocks based on technical patterns, fundamentals, trends, and AI-driven signals, allowing me to quickly compare names like HYPD against peers in the digital-asset space and identify relevant setups without manual screening. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: HYPD

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


HYPD's RSI Oscillator climbs out of oversold territory

The RSI Indicator for HYPD moved out of oversold territory on October 20, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 32 similar instances when the indicator left oversold territory. In 29 of the 32 cases the stock moved higher. This puts the odds of a move higher at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +5.02% 3-day Advance, the price is estimated to grow further. Considering data from situations where HYPD advanced for three days, in 187 of 226 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.

HYPD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 04, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on HYPD as a result. In 68 of 75 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.

The Moving Average Convergence Divergence Histogram (MACD) for HYPD turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 36 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 86%.

HYPD moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for HYPD crossed bearishly below the 50-day moving average on October 19, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

The 50-day moving average for HYPD moved below the 200-day moving average on November 10, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where HYPD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for HYPD entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 32 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 47 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.380) is normal, around the industry mean (3.498). P/E Ratio (-0.664) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (25.707) is also within normal values, averaging (440.869).

The Tickeron Price Growth Rating for this company is 77 (best 1 - 100 worst), indicating slightly worse than average price growth. HYPD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HYPD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.23B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 2%. For the same Industry, the average monthly price growth was -6%, and the average quarterly price growth was -17%. PEPG experienced the highest price growth at 117%, while KPTI experienced the biggest fall at -71%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -49%. For the same stocks of the Industry, the average monthly volume growth was -24% and the average quarterly volume growth was -33%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 43
Price Growth Rating: 65
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -4 (-100 ... +100)
1-on-1 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a company which delivers sight saving therapies

Industry Biotechnology

Industry
Pharmaceuticals Major
Address
23461 South Point Drive
Phone
+1 833 393-6684
Employees
9
Web
https://www.hyperiondefi.com
Interact to see
Advertisement
BZ dropped sharply, sliding from a $16.72 prior close to $13.48 (-19.38%), with the decline beginning in premarket and deepening into the early regular session. No verified company-specific news or fundamental catalyst was issued; the fall tracked a broad China ADR selloff (the Nasdaq Golden Dragon index slid more than 2%), but that alone is too small to explain a ~20% drop — the stock's Hong Kong listing fell only -2.6%.
The $1.14 central target is not an analyst consensus; it is the all-cash merger consideration in GoPro, Inc. (GPRO) 's pending deal with Starman Optical, agreed in September 2026. With the stock trading near $0.88, reaching $1.14 would require a move of roughly 29.5%.
NBIS fell from $154.69 to $129.12, down -16.53%, with the decline starting in premarket trading and continuing through the regular session. The drop followed Q3 results: revenue of $980.8M (+571% YoY) beat estimates, but management cut 2026 revenue guidance to the low end of its range on third-party capacity delays and raised 2026 capex to roughly $27B, reviving financing and execution fears.
The central target of $21 is the arithmetic mean of three recently attributable analyst price targets on RUM — $25 (Lake Street), $15 (Texas Capital), and $22 (Maxim Group) — which average roughly $20.67. With shares trading near $5.90 after a post-earnings surge, reaching $21 would require a gain of roughly 256%, a very large move.
The $1 target in this article is not an analyst price target; it is the $1.00 Nasdaq minimum bid price requirement, the level Cenntro itself has publicly targeted through a 1-for-60 reverse stock split. Cenntro trades near $0.12 per share, meaning reaching $1 would require an increase of roughly 730%—an exceptionally large move.